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Abstract
Background: A case report to highlight the association between rifabutin and hypopyon
Methods: A 56 year old male presented with a one day history of blurred vision in his right eye.
He had an established diagnosis of Crohn's disease which was in remission following treatment with
rifabutin and clarithromycin. A brisk anterior uveitis with hypopyon and a mild vitritis was detected
in the right eye. The acute inflammatory episode resolved following treatment with topical
corticosteroids and withdrawal of rifabutin.
Results: The presence of hypopyon is atypical in uveitis associated with inflammatory bowel
disease. The association between rifabutin treatment and hypopyon uveitis is well recognised in
Mycobacterium avium paratuberculosis. However, use of rifabutin in the management of Crohn's
disease is controversial and not widely known to an ophthalmic readership.
Conclusion:  This report highlights the importance of keeping abreast of novel therapeutic
developments in systemic conditions likely to be encountered in ophthalmology.
Background
Crohn's disease is a chronic granulomatous inflammatory
disease which affects multiple sites throughout the gastro-
intestinal system. The ocular manifestations are protean
and commonly include episcleritis, scleritis and anterior
uveitis[1]. Retinal vasculitis, optic neuropathy and multi-
focal choroiditis have also been reported [2-4]. In this
report we describe a case of panuveitis with hypopyon in
a patient with Crohn's disease in whom the presentation
was attributable to a therapeutic agent and not the under-
lying systemic condition.
Methods
A 56 year old male attended the eye clinic having awoken
with blurred vision in his right eye; pain and photophobia
were not present. A 15 year history of Crohn's was
reported – this was in remission following a year-long trial
of 300 mg rifabutin daily with clarithromycin 250 mg
daily. Azathioprine had been discontinued by his rheu-
matologist 2 weeks previously. The patient had never
undergone gastro-intestinal surgery, there was no arthritis
and no previous history of uveitis. He was HLA-B27 nega-
tive. At presentation the best corrected visual acuity was 6/
24 OD and 6/6 OS. There was a right anterior uveitis with
4 mm hypopyon (Figure 1). The IOP was 12 mmHg in
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both eyes. There was moderate vitreous activity in the
right eye; no features suggestive of retino-choroidal
inflammation or vasculitis were detected and the optic
disc was healthy. The left eye was quiet, with no evidence
of intra-ocular inflammation. Blood tests including a full
blood count, erythrocyte sedimentation rate and C-reac-
tive protein were all within the normal range, in keeping
with a state of remission.
A diagnosis of right acute panuveitis was made and the
patient was commenced on hourly topical dexametha-
sone 0.1% and cyclopentolate 1% twice daily. The patient
discontinued rifabutin, pending rheumatology review the
following week. Within three days, the hypopyon had
reduced to 1 mm and the vision had improved to 6/9 in
the right eye; a reducing course of dexamethasone was
instituted. One week after discontinuing rifabutin and
clarithromycin, azathioprine 50 mg twice daily was
restarted by his rheumatologist. At 4 weeks, the IOP in the
right eye had elevated to 38 mmHg – this was ascribed to
steroid response and was managed using topical dorzola-
mide, timolol and by substituting dexamethasone for
rimexolone 1% bd. Following a further 8 weeks on this
management, the anterior uveitis and ocular hypertension
completely resolved and all topical medications were dis-
continued. At this stage, the patient's inflammatory bowel
disease was managed using azathioprine 50 mg twice
daily, prednisolone 12.5 mg once a day and alendronate
70 mg once
Discussion
Acute anterior uveitis occurs in approximately 4% of
patients with Crohn's disease. Presentation with
hypopyon is unusual and raises suspicion of either alter-
native systemic inflammatory disorders such as Behçet's
or ankylosing spondylitis or, as in this case, an exogenous
factor. Hypopyon uveitis is well recognised following
rifabutin therapy for mycobacterium avium intracellulare
in both immuno-compromised and immuno-competent
subjects[5,6]. In these reports, hypopyon could occur
bilaterally and usually responded rapidly following com-
mencement of topical corticosteroids, with or without
reduction of rifabutin dosage[7]. Presentation with
hypopyon often occurs several months after starting rifab-
utin. In this case the presence of hypopyon, and rapid ini-
tial improvement following withdrawal of rifabutin,
suggest rifabutin as the underlying aetiology. There is a
possibility that the recent discontinuation of azathioprine
may have contributed to a generalised inflammatory
relapse, of which the uveitis was part of; this was not,
however, clinically apparent during the acute presenta-
tion. The protracted subsequent recovery is atypical,
although the steroid response will undoubtedly have con-
tributed to this.
The use of rifabutin to treat Crohn's disease is not familiar
to an ophthalmic readership; a previous case of anterior
uveitis has been reported in the general medical literature
only[8]. A suspected aetiology of exposure to Mycobacte-
rium avium subspecies has been proposed in Crohn's dis-
ease. A particular role for rifabutin has been noted in
patients with proven evidence of Mycobacterium avium
infection, although this was not the case in this subject[9].
Previous studies reported pharmacokinetic interactions
when combining rifabutin and clarithromycin leading to
an increase in rifabutin levels, resulting in an increase fre-
quency of uveitis, this could explain the acute onset of
uveitis in our case[10].
Conclusion
The use of rifabutin to treat Crohn's disease is controver-
sial and is currently used on a trial or named patient basis
in the UK. This report, however, does highlight the impor-
tance of keeping abreast of novel therapeutic develop-
ments in systemic conditions likely to be encountered by
an ophthalmologist.
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